Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
SORD Research
…some of the advances in the eventual treatment of axon degeneration may be applicable as these therapies are developed. If your type is not yet identified, please visit a CMTA…
CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT
…global leadership in advancing treatments for CMT and it underscores the association’s commitment to improving the lives of those who have CMT, while strengthening its dedication to developing treatments and,…
CMTA Updates List of Neurotoxic Meds Potentially More Hazardous to CMT Patients
…than for people who do not have CMT. The reviewers emphasized the importance of not denying patients with CMT treatments that may prolong life expectancy for cancer or improve their…
CMTA Lunch & Learn: Neuro-Toxic Medication List Update
07/13/2023 @ 12:00 pm – 1:00 pm – Please join us on July 13 at 12:00 p.m. Eastern Time to hear an update on the newly reviewed and revised CMT Neuro-toxic Medication List. The CMTA funded a grant awarded to Guido Cavaletti, MD at the University of Milano-Bicocca to review and update the current CMT neuro-toxic medication list. Dr. Cavaletti and colleague, Dr. […]
Vera Fridman, MD joins the CMTA STAR Advisory Board
…on paving the way for, and executing, treatment trials for neuropathy. Dr. Fridman’s research aims to address the barriers to effective clinical trials in Charcot-Marie-Tooth (CMT) disease through the execution…
What is CMT?
…legs, progressive sensory loss, and CMT can affect other parts of the body. This leads to problems with balance, walking, hand use, and more. There currently is no treatment or…
Gene Therapy Advances for CMT4J, CMT4A and GAN
…a gene therapy for one rare form of CMT called Giant Axonal Neuropathy, and aims to develop similar gene therapy treatments for other forms of CMT. Dr. Gray is a…
CMTAreportFall2023Spreads
…further accelerate progress. The CMTA is committed to supporting clinical trial readiness and roll-out for CMT and we look forward to the next chapter of this treatment’s development.” DTx Pharma…
FallReportSpreads
…further accelerate progress. The CMTA is committed to supporting clinical trial readiness and roll-out for CMT and we look forward to the next chapter of this treatment’s development.” DTx Pharma…
CMTAreportFall2023forwebspreads
…further accelerate progress. The CMTA is committed to supporting clinical trial readiness and roll-out for CMT and we look forward to the next chapter of this treatment’s development.” DTx Pharma…